| Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics SA Polyzos, J Kountouras, CS Mantzoros Metabolism 92, 82-97, 2019 | 980 | 2019 |
| Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines SA Polyzos, J Kountouras, C Zavos Current molecular medicine 9 (3), 299-314, 2009 | 399 | 2009 |
| Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis SA Polyzos, KA Toulis, DG Goulis, C Zavos, J Kountouras Metabolism 60 (3), 313-326, 2011 | 363 | 2011 |
| Adipokines in nonalcoholic fatty liver disease SA Polyzos, J Kountouras, CS Mantzoros Metabolism 65 (8), 1062-1079, 2016 | 357 | 2016 |
| The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease SA Polyzos, J Kountouras, C Zavos, E Tsiaousi Diabetes, Obesity and Metabolism 12 (5), 365-383, 2010 | 349 | 2010 |
| Clinical features of 24 patients with rebound‐associated vertebral fractures after denosumab discontinuation: systematic review and additional cases AD Anastasilakis, SA Polyzos, P Makras, B Aubry‐Rozier, S Kaouri, ... Journal of Bone and Mineral Research 32 (6), 1291-1296, 2017 | 327 | 2017 |
| Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals HS Moon, M Dalamaga, SY Kim, SA Polyzos, OP Hamnvik, F Magkos, ... Endocrine reviews 34 (3), 377-412, 2013 | 300 | 2013 |
| The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related … VG Athyros, TK Alexandrides, H Bilianou, E Cholongitas, M Doumas, ... Metabolism 71, 17-32, 2017 | 291 | 2017 |
| The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review SA Polyzos, J Kountouras, C Zavos, G Deretzi Helicobacter 16 (2), 79-88, 2011 | 284 | 2011 |
| Irisin in metabolic diseases SA Polyzos, AD Anastasilakis, ZA Efstathiadou, P Makras, N Perakakis, ... Endocrine 59, 260-274, 2018 | 263 | 2018 |
| Pharmacotherapy of obesity: available medications and drugs under investigation E Pilitsi, OM Farr, SA Polyzos, N Perakakis, E Nolen-Doerr, ... Metabolism 92, 170-192, 2019 | 262 | 2019 |
| Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis SA Polyzos, KN Aronis, J Kountouras, DD Raptis, MF Vasiloglou, ... Diabetologia 59, 30-43, 2016 | 262 | 2016 |
| Irisin in patients with nonalcoholic fatty liver disease SA Polyzos, J Kountouras, AD Anastasilakis, EV Geladari, CS Mantzoros Metabolism 63 (2), 207-217, 2014 | 256 | 2014 |
| Leptin in nonalcoholic fatty liver disease: a narrative review SA Polyzos, J Kountouras, CS Mantzoros Metabolism 64 (1), 60-78, 2015 | 244 | 2015 |
| Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives M Dalamaga, SH Chou, K Shields, P Papageorgiou, SA Polyzos, ... Cell metabolism 18 (1), 29-42, 2013 | 228 | 2013 |
| Clinical complications following thyroid fine‐needle biopsy: a systematic review SA Polyzos, AD Anastasilakis Clinical endocrinology 71 (2), 157-165, 2009 | 222 | 2009 |
| Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition AD Anastasilakis, SA Polyzos, ZG Saridakis, G Kynigopoulos, ... The Journal of Clinical Endocrinology & Metabolism 99 (9), 3247-3255, 2014 | 217 | 2014 |
| Pharmacotherapy of type 2 diabetes: an update J Upadhyay, SA Polyzos, N Perakakis, B Thakkar, SA Paschou, N Katsiki, ... Metabolism 78, 13-42, 2018 | 216 | 2018 |
| Sarcopenic obesity SA Polyzos, AN Margioris Hormones 17, 321-331, 2018 | 208 | 2018 |
| Adipose tissue, obesity and non-alcoholic fatty liver disease. SA Polyzos, J Kountouras, CS Mantzoros Minerva endocrinologica 42 (2), 92-108, 2016 | 207 | 2016 |
